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Abstract 
Objective: Rheumatoid arthritis (RA) associates with excessive cardiovascular 
morbidity and mortality.  Hypertension (HT) contributes significantly to the 
development of cardiovascular disease (CVD).  Little is known about the factors that 
influence blood pressure (BP) in patients with RA. In this study, we assessed the 
prevalence of HT in a secondary care cohort of RA patients, and aimed to identify 
factors associated with its presence and inadequate control. 
Methods: A total of 400 consecutive RA patients were studied.  HT was defined as 
systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg, or current use of 
antihypertensive drugs. The association of HT with several demographic and RA-
related factors, co-morbidities and drugs was evaluated using logistic regression. 
Results:  HT was present in 282 (70.5%) patients.  Of those, 171 (60.6%) received 
antihypertensive therapy, but 111 (39.4%) remained undiagnosed.  Of those treated, 
only 37/171 (21.8%) were optimally controlled.  Multivariable logistic regression 
revealed age (OR=1.054, CI: 1.02 to 1.07, p=0.0012),  BMI (OR=1.06, CI: 1.003 to 
1.1213, p=0.038) and prednisolone use (OR=2.39, CI: 1.02 to5.6, p=0.045) to be 
independently associated with the presence of HT. BMI (OR=1.11, CI: 1.02 to 1.21, 
p=0.002) and the presence of CVD (OR=4.01, CI: 1.27 to 12.69, p=0.018) associated 
with uncontrolled HT. 
Conclusions:  HT is highly prevalent in RA, under-diagnosed particularly in the 
young, and under-treated particularly in old RA patients with CVD.  RA patients 
receiving steroids should be specifically targeted for screening and treatment; those 
with any cardiovascular co-morbidity may require particularly aggressive monitoring 
and treatment strategies.   
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Introduction 
Rheumatoid arthritis  (RA) associates with increased cardiovascular mortality 
due to increased prevalence of co-morbidities such as Myocardial Infarction (MI), 
stroke and Heart Failure (HF) [1,2]. The adjusted relative risk of MI in women with RA 
compared to those without RA is estimated to be around 2.0 [2], while acute coronary 
syndromes may present atypically and recur more frequently in patients with RA [3]. 
Increased clinical suspicion may aid early identification and appropriate management 
of risk factors in these patients [1].  
HT is quantitatively the most important modifiable risk factor for 
cardiovascular disease (CVD), being more common than cigarette smoking, 
dyslipidaemia, or diabetes [4]. In the INTERHEART study [5], which included patients 
from 52 countries, HT accounted for 18% of the population attributable risk of a first 
MI. HT increases the risk of both coronary artery disease and cerebrovascular 
disease in the general population [6]. It remains unclear whether HT is commoner in 
RA [7-9]. 
Aging and obesity are known predictors of HT in the general population; 
smoking cessation and low grade inflammation may also contribute to the 
development of HT [10]. In RA, the chronic inflammatory burden may lead to 
increased arterial stiffness [11], one of the physical causes of raised systolic BP, 
providing a potential link between inflammation and HT in this disease. Drugs 
commonly administered to RA patients, such as the non Steroidal Anti-Inflammatory 
Drugs (NSAIDs), cyclo-oxygenase II inhibitors (Coxibs) [12], oral steroids [13] and 
some disease-modifying anti-rheumatic drugs (DMARDs), such as leflunomide [14] 
and cyclosporin [15] may also cause major or minor increments in BP levels.  Co-
morbidities common in RA, such as insulin resistance [16], dyslipidaemia [17] and 
renal disease, have also been shown to associate with essential HT in the general 
population [18,19]. To date, no studies have investigated the potential association of 
HT with these factors in patients with RA.  
In the present study we aimed: (i) to identify the overall prevalence of HT in a 
large secondary care population with RA, and estimate whether undiagnosed and/or 
sub-optimally controlled HT is a common problem in these patients; and (ii) to identify 
factors that may associate with the presence and/or insufficient control of HT in RA. 
 
Patients and Methods 
Four hundred consecutive patients with RA meeting retrospective application 
of the 1987 revised ACR criteria [20], attending routine outpatient clinics at the 
Department of Rheumatology of the Dudley Group of Hospitals, Dudley (Black 
Country), West Midlands, UK,  were enrolled in this cross-sectional, one-centre 
study.  The study had local Research Ethics Committee and Research and 
Development approval and all participants gave their written informed consent 
according to the Declaration of Helsinki.  
Basic demographic and clinical characteristics of the study population are 
shown in Table 1. All participants underwent a thorough baseline evaluation including 
a detailed review of their medical history and hospital records, physical examination, 
and contemporary assessments of height, weight, body mass index (BMI), body 
composition (using a TANITA Body Composition Analyzer BC-418), current disease 
activity score (DAS28) [21] and physical function using the Health Assessment 
Questionnaire (HAQ) [22]. All medications and their exact indication were recorded, 
including loop and thiazide diuretics, beta-blockers, angiotensin-converting enzyme 
inhibitors (ACE-I) and Angiotensin-II receptor antagonists (ARBs), dihydropyridine 
and non-dihydropyridine calcium channel blockers, a-adrenoreceptor blockers, 
centrally acting antihypertensives, other antihypertensives, oral daily prednisolone, 
paracetamol, NSAIDs, Coxibs and DMARDs. Oral prednisolone dose was defined 
as low if <7.5mg/day, medium if ≥7.5mg/day and high if >30mg/day [23]. 
Blood pressure (BP) was the mean of three measurements taken at five 
minute intervals on the right arm with the patient in a seated position after at least 
five minutes rest, using an appropriately sized cuff of the CRITICARE 506DXN 
machine (Systems Inc).  The presence of HT was defined as a systolic BP≥140 
and/or diastolic BP≥90 and/or the use of antihypertensive medications, according to 
the British HT Society/NICE guidelines [24] .  Patients were divided in two main 
groups: normotensives and hypertensives. Those with HT were sub-divided into: 
controlled HT  [if they were receiving medication specifically prescribed for HT and 
had SBP<140 mmHg and DBP<90 mmHg (if they had no CVD or diabetes mellitus-
DM) or SBP<130 mmHg and DBP<80 mmHg (if they had CVD or DM)]; 
uncontrolled HT  (if SBP or DBP were higher than the above values while on 
treatment);  untreated HT (if SBP≥140 mmHg or DBP≥90 and the patient was not on 
anti-hypertensive therapy).  
Patients were classified as having CVD (RA+CVD) if they had a positive 
history of any of the following: MI, stroke or Transient Ischaemic Attack (TIA), 
Peripheral Vascular Disease (PVD), angioplasty, coronary artery bypass grafting 
(CABG), or if they had a positive Rose questionnaire [25] on assessment. Patients 
were defined as being diabetic when fasting glucose levels were >7mmol/L and/or 
oral hypoglycemic medication or insulin was used.  Number of pack-years of smoking 
was recorded and patients were categorised as current smokers, ex smokers, never 
smoked.  
Venous blood was collected in the fasting state on the same day and a wide 
range of tests was performed.  All biochemical tests were carried out in the 
Biochemistry Laboratory of Russells Hall hospital, Dudley Group of hospitals NHS 
Trust, UK. Biochemical estimations included: fasting lipids, complete serum 
biochemistry, fasting glucose, fasting insulin and C-reactive protein (CRP).  Insulin 
Resistance (IR) was evaluated from fasting glucose and insulin using the 
Homeostasis Model Assessment of IR (HOMA IR) [26] and the Quantitative Insulin 
sensitivity Check Index (QUICKI)[27], and was defined as the presence of DM or 
HOMA IR ≥ 2.5 or QUICKI ≤ 0.333. Renal function was assessed by GFR estimation 
using the six-variable Modification of Diet in Renal Disease (MDRD) equation [28].     
 
Statistical analysis 
 The Kolmogorov-Smirnov test was used to evaluate whether each parameter 
followed a Gaussian distribution. Values were expressed as mean ± standard 
deviation (SD), median (25-75th percentile values) or percentages, as appropriate. 
Comparisons were performed by Student’s t-test, Mann Whitney U test, and Chi-
square test for normally distributed, non-normally distributed and categorical 
variables, respectively. 
Binary logistic regression analysis was used to evaluate the independence of 
the factors associated with HT status and the differences between the “controlled HT” 
and “uncontrolled HT” groups.  
Differences were considered to be significant at a p value of <0.05 (two-
tailed). All analyses were carried out with SPSS 13.0 (SPSS Inc, Chicago, Illinois). 
 
Results  
Descriptive characteristics of the population studied: 
The cohort consisted almost exclusively (96%) of Caucasians (reflecting the 
local demographic split) and were predominantly (~73%) females.  The mean age 
(SD) was 61.56 ± 12.02 years, and the mean ± SD systolic and diastolic BP were 
142.24 ± 20.74 and 78.85 ± 11.24 mmHg respectively.  
Of the 400 patients, 350 (87.5%) were on DMARDs: 225 (56.3%) on 
methotrexate, 118 (29.5%) on sulphasalazine, 80 (20%) on hydroxychloroquine, 46 
(11.5%) on anti Tumor Necrosis Factor alpha (anti-TNFα) therapy, 16 (4%) on 
leflunomide, 7 (1.8%) on azathioprine, and 2 (0.5%) on cyclosporin; 227 (56.8%) 
patients were on DMARD monotherapy, while 123 (30.8%) were on combination 
therapy of two or more DMARDs.  One hundred and twenty five patients (31.3%) 
were taking daily oral prednisolone, [54 (13.4%) low dose, 71 (17.9%) medium 
dose and 0 (0%) high dose]; 79 (19.8%) NSAIDs and 32 (8%) Coxibs.  
There were 118 (29.5%) normotensive and 282 (70.5%) hypertensive patients 
(male vs. female: 79.6% vs. 67.1%, p=0.015). From those with hypertension, 171 
(60.6%) had been diagnosed and were on antihypertensive medications and 111 
(39.4%) had undiagnosed/untreated HT (males vs. females; 35.3% vs. 41.3, p=6.37).  
Undiagnosed/untreated HT was significantly commoner in the younger age groups 
(35-44 years: 76.2%;  45-54 years: 51.6%) than in older age deciles (55-64 years: 
34.5%;  65-74 years: 37.9%;  75+ years: 25%) (p=0.003) (Figure 1).  From the 171 
diagnosed hypertensives on treatment, 37 (21.63%) had controlled HT and 134 
(78.36%) had uncontrolled HT. Uncontrolled HT was more common in older (p=0.003 
– Figure 1) and overweight/obese patients (p=0.029 – Figure 2).  Average control 
rate (controlled HT divided by total HT) was 37/282 (13.12%).  This was very poor in 
the younger age group (35-44 years: 4.8%) and older age groups (65-74 years: 
10.7%;  75+ years: 7.5%), and poor in the middle-aged patients (45-54 years: 19,4%, 
55-64 years: 19%). 
 
Differences according to hypertensive status: 
Hypertensive RA patients, when compared to normotensives, were older 
[65.35 (57.55-71.22) vs. 58.86 (46.82-66) years, p<0.001], more often male (30.5% 
vs. 18.6%, p=0.015), had higher BMI (28.27±4.98 vs. 26.42±4.9, p=0.001), were 
more often past cigarette smokers (43.5% vs. 26.7%, p=0.005) and users of medium 
dose prednisolone (21.5% vs. 9.3%, p=0.004), and were more likely to have IR 
[(44.7% vs. 22.3%, p<0.001): diabetes 8.9% vs. 2.5%, p=0.015;  HOMA IR 2.06 
(1.27-3.52) vs. 1.52 (0.93-2.37), p<0.001; QUICKI 0.34 (0.32-0.37) vs. 0.36 (0.33-
0.39), p<0.001].  They also had higher lipid levels [TCHOL (5.54±1.16 vs. 5.26±1 
mmol/L, p=0.032) and TG 1.3 (1-1.6) vs. 1.1 (0.9-1.5) mmol/L, p=0.013)] and worse 
renal function (79.13±21.63 vs. 88.56±18.76 ml/min/1.73m2, p<0.001). There were no 
significant differences between hypertensive and normotensive RA patients in the 
levels of current inflammation (ESR, CRP, DAS28), physical dysfunction (HAQ) or 
the use of NSAIDs, Coxibs, leflunomide or other DMARDs. 
Patients with uncontrolled HT, compared to those with controlled HT, were 
not significantly older (66.22±10.32 vs. 62.7±9.28 years, p=0.06), but had 
significantly higher BMI (28.97±5.12 vs. 26.87±4.83, p=0.03) and prevalence of CVD 
(36.8% vs. 13.5%, p=0.007). ACE-I/ARBs were used more frequently in the 
uncontrolled HT group compared to patients with controlled HT (63.9% vs.45.9%, 
p=0.049); there were no differences in any of the other classes of anti-hypertensive 
drugs (Table 2). 
Multivariable analysis 
A logistic regression model including age, sex, BMI, smoking habit, total 
cholesterol, TG, IR, full MDRD, use of medium dose prednisolone, NSAIDs/Coxibs, 
leflunomide and statins was utilized in order to evaluate which factors were 
independently associated with the presence of HT. Variables that retained 
significance were age (OR=1.05, CI: 1.02 to1.07, p<0.001), BMI (OR=1.06, CI: 1.003 
to1.121, p=0.038) and use of medium dose prednisolone (OR=2.39, CI: 1.02 to 5.6, 
p=0.045). 
A similar approach was used to identify factors that may associate with sub-
optimal BP control in RA patients.  The basic model included age and sex, the factors 
that were significant in the univariable analysis above (BMI and presence of CVD) 
and the four main classes of antihypertensive drugs (thiazide diuretics, b-blockers 
ACE-I and dihydropyridine calcium channel blockers). Increasing BMI (OR=1.11, CI: 
1.02 to 1.21, p=0.018) and presence of CVD (OR=4.01, CI: 1.27 to 12.69, p=0.018) 
retained their significant association with sub-optimal BP control, while no other 
factors transpired as being significant.   
 
Discussion 
The overall prevalence of HT in this secondary care cohort of RA patients 
with a mean age of 62 years was high at 70%: this is higher even than the highest 
HT prevalence in England, observed in those over 75 years of age in the 2003 
National Health Survey for England (NHSE) [29], and appears to be present 
consistently in both male and female RA patients of all age groups. In our study, 
assessment of BP was based on the mean of three clinic measurements: this may 
not be as reliable as 24h BP monitoring, which can rule out cases of white-coat HT 
[30]. However, the NHSE was also based on 3 BP measurements to define HT, so 
the increased prevalence observed in our cohort could not be due to such 
misclassification.   The NHSE was community-based, whereas our cohort was 
exclusively from secondary care, thus the prevalence of HT in the overall population 
of RA patients may have been overestimated.  In addition, our study did not assess 
local population controls.  It is well-established that the prevalence of HT may vary 
from locality to locality, with northern UK regions having higher HT rates than regions 
in the South in both sexes after standardization for age [31].  However, a recent 
survey from the geographically neighbouring (<6 miles) Wolverhampton, also in the 
Black Country, estimated the overall prevalence of HT in the adult non-diabetic local 
population at 28%, virtually identical with the national average [32]. 
A significant proportion of hypertensive RA patients in this cohort (35% of 
males and 41% of females) were undiagnosed and thus untreated.  Again this is 
higher than the NHSE (males 6.4%-33.1%, females 1.7%-33.9%) and is quite 
disappointing, since RA patients are both regular attendees to hospital clinics and 
frequent users of primary care services [33], so they have ample opportunity to be 
monitored for their BP.  It is particularly alarming that undiagnosed HT was much 
commoner in the young RA patients, i.e. those who have most to benefit by early 
identification and treatment.  Even in those patients who were diagnosed and treated 
for HT, the control rate was significantly lower, at 13.2%, than that observed in 
general population hypertensive males (21.5%) and females (22.8%) [34].  In the 
younger patients, this poor control rate was predominantly due to the fact that they 
remained undiagnosed, whereas in the older patients and those with CVD, it was 
because desirable targets were not met, probably due to either sub-optimal therapy 
or lack of adherence [35], both of which may result from the polypharmacy that 
characterizes many patients with RA [36].  We used a stricter definition of optimal 
control (<140/90 mmHg for patients without DM or CVD, <130/80 mmHg for those 
with DM or CVD) compared to that used in the NHSE (<140/90 mmHg, regardless of 
the presence of DM or CVD), but even applying the same definition, the proportion of 
RA patients with sub-optimal BP control was considerable.  Optimal antihypertensive 
therapy has been associated with 40% mean reductions in stroke incidence, 20% in 
MI and more than 50% in heart failure [37] in the general population.  Such an 
additional burden of uncontrolled hypertension may lead to additional strokes and 
MIs and explain part of the increased cardiovascular morbidity and mortality of RA.  
Similarly increased HT prevalence and poor control was also a characteristic of 
patients with type 2 DM, but the implementation of aggressive, systematic screening 
and management in this patient group appears to have improved BP control [38] and 
overall cardiovascular outcomes [39] in the last decade.  The parallels between RA 
and type II DM, in the context of CVD, have been previously drawn [1] with a 
suggestion that equally aggressive screening and management programs should be 
established for RA patients.  Regular CVD risk assessment has now been formally 
proposed by the Arthritis and Musculoskeletal Alliance (ARMA) [40] as one of the 
standards of care for RA patients, but does not appear to have become common 
practice yet [40], at least in the UK. 
One of the main aims of the present study was to identify factors that may 
associate with HT in RA: this may be useful both for future pathogenic studies and for 
the identification of patients that may need to be specifically targeted for screening 
and intervention in the routine clinical setting.  Significant univariable associations 
were found with previous smoking habit and with insulin resistance, mirroring what 
has previously been described in the general population [10].  However, these 
associations did not remain robust in multivariable analysis, which suggested that 
these associations may have been mediated through increasing BMI.  This is in 
agreement with other studies in the general population, which show that overweight 
and obesity are important mediators of hypertension, in the context of ex-smokers 
[41] with insulin resistance [42], and associate with current or future HT and relevant 
end-organ damage in non-RA populations.  Indeed the only demographic / 
anthropometric characteristics that remained strongly independently associated with 
HT in this RA cohort were advancing age and increasing obesity. The latter may be 
particularly important, as it has recently been suggested that the cut-offs for the 
classification of RA patients into overweight and obese categories should be lowered 
to a BMI of 23 and 28 respectively, to reflect their altered body composition [43]. 
Polypharmacy is a characteristic of many patients with RA [36] and many of 
the drugs used have the potential to cause major or minor increments in BP levels. In 
the present study there was no obvious association between HT and the use of either 
NSAIDs/Coxibs or relevant DMARDs (leflunomide and cyclosporin).  The latter may 
be simply due to the very small number of patients receiving these drugs in the 
cohort studied.  The former is more difficult to explain, as the evidence for their 
association with HT is compelling [1,12].  The exact frequency and dosing regimen 
prescribed was available, but the exact way these drugs were actually used by 
patients was not investigated or even recorded in detail in this study:  it is well known 
that adherence to therapy may be low in RA in routine clinical practice, in 
contradistinction to randomized controlled trials which usually associate with high(er) 
adherence rates [35].  However, the most important reason may be the cross-
sectional design of this study, which leads to conclusions that can only serve for 
hypothesis-generation, than provide proof of causality or directionality of any of the 
associations found.   A good example of this is the significant association found in 
this cohort between HT and the use of medium dose (≥7.5 mg/day) of oral 
prednisolone, but not with any of the laboratory or clinical assessments of current 
inflammation that were used (ESR, CRP or DAS28).  This association could be either 
due to possible hypertensive effects of steroids, or due to the selection of patients 
with high inflammatory burden who require steroids for disease control.  Indeed there 
is conflicting evidence for both in the literature.  Studies have correlated raised 
endogenous cortisol levels and high BP [44], though not in patients with RA  .  In 129 
asthmatic and 66 RA patients it has been suggested that “low” dose prednisolone 
(defined to be <20mg/day) cannot cause significant BP increments [13]. The link 
between steroid exposure and HT is not well understood [44], but increased 
peripheral vascular sensitivity to adrenergic agonists [45], increased hepatic 
production of renin substrate (angiotensinogen) and activation of renal tubular type 1 
(mineralocorticoid) receptors by cortisol [46] have all been proposed as potential 
mechanisms.   However, increased levels of systemic inflammation have also been 
associated with HT in the general population.  A prospective cohort study [47] has 
recently demonstrated  that CRP levels associate with future development of HT.  
Increased inflammatory load has been associated with worse overall and CVD 
outcomes in RA [1,48], but not directly with HT.  We have not collected “historical” 
data of the extent of systemic inflammation in relation to when HT developed in the 
RA patients of this cohort, but it would be interesting to study this in prospective 
cohorts of inflammatory arthritis, such as the Norfolk Arthritis Register (NOAR) [49] or 
others. 
Finally, the present study aimed to identify factors that may associate with 
sub-optimal BP control in patients with RA.  Robust associations were found between 
uncontrolled BP, increasing BMI and the presence of CVD, the latter because target 
BP is lower (<130/80) than general (<140/90).  This would suggest that older, 
overweight RA patients with prevalent CVD should be specifically targeted for 
aggressive monitoring and treatment of their BP.  This may be particularly difficult in 
these patients: none of the antihypertensive medications in the present study 
appeared to be superior to the others and the increased frequency of usage of ACE-
I/ARB in uncontrolled hypertensive RA patients may simply mirror the higher rates of 
prevalent CVD and DM.  It is likely that these patients require combination 
antihypertensive therapy, with very close monitoring due to their polypharmacy [36], 
co-morbidities [50] and adherence characteristics [35].  
In conclusion, this cross sectional study suggests an increased prevalence 
and low control rates of HT in secondary care RA patients compared to the general 
population of England.  This may be of importance in the context of the increased 
cardiovascular morbidity and mortality of RA.  Systems for surveillance, adequate 
treatment and ongoing monitoring for these patients need to be put in place both in 
primary and secondary care.  The young, and elderly overweight RA patients should 
be specifically screened for undiagnosed HT, while those with prevalent CVD need 
aggressive monitoring and treatment strategies to achieve recommended BP targets 
[51].  
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Table 1:  Demographic, clinical and laboratory characteristics of the study population 
  Total (N=400) no HTN (N=118) HTN (N=282) p value 
General demographics 
Age (years) 63.1 (55.5-69.6) 58.86 (46.82-66) 65.35 (57.55-71.22) <0.001 
Sex female n(%) 292 (73) 96 (81.4) 196 (69.5) 0.015 
Smoking status n(%) 
   never smoked 
   ex smokers 
 
171 (45) 
145 (38.2) 
   current smokers 64 (16.8) 
 
59 (50.9) 
31 (26.7) 
26 (22.4) 
 
117 (42.4) 
120 (43.5) 
39 (14.1) 
0.005 
Pack years 3 (0-20) 0.5 (0-20) 5 (0-20) NS 
RA characteristics     
General characteristics     
  RF positive n(%)   296 (75.7) 86 (74.8) 210 (76.1)  
  antiCCP positive n(%) 198 (66.4) 51 (63.8) 147 (67.4) NS 
  Disease duration (years) 10 (4-18) 9.5 (4-17.25) 10 (4-19) NS 
Disease activity 
  CRP (mg/L) 8 (5-20) 9 (4-18.25) 8 (5-20) NS 
  ESR 21 (9-36.5) 9 (5-17) 10 (5-22) NS 
  DAS 28 4.21±1.4 4.23±1.49 4.21±1.37 NS 
Disease severity 
  HAQ 1.5 (0.63-2.13) 1.63 (0.59-2) 1.5 (0.63-2.25) NS 
  EAD  n(%) 269 (67.3) 77 (65.3) 192 (68.1) NS 
  Joint replacement surgery n(%) 116 (29) 37 (31.4) 79 (28) NS 
Medication     
DMARDs n(%) 350 (87.5) 104 (88.1) 246 (87.2) NS 
MTX n(%) 225 (56.3) 71 (60.2) 154 (54.6) NS 
antiTNF n(%) 46 (11.5) 14 (11.9) 32 (11.3) NS 
leflunomide n (%) 16 (4) 6 (5.1) 10 (3.5) NS 
prednisolone n(%) 125 (31.3) 28 (23.7) 97 (34.4) 0.036 
prednisol medium dose n(%) 71 (17.9) 11 (9.3) 60 (21.5) 0.004 
NSAID n(%) 79 (19.8) 27 (22.9) 52 (18.4) NS 
COX II inhibitors n(%) 32 (8) 10 (8.5) 22 (7.8) NS 
statin n(%) 78 (19.5) 10 (8.5) 68 (24.1) <0.001 
Comorbidities     
Dyslipidaemia     
  Hypercholesterolaemia history n(%) 78 (19.5) 12 (10.2) 66 (23.4) 0.002 
  Total CHOL mmol/L1 5.44±1.15 5.26±1 5.54±1.16 0.032 
  TG mmol/L1 1.2 (0.9-1.6) 1.1 (0.9-1.5) 1.3 (1-1.6) 0.013 
  HDL mmol/L1 1.6 (1.3-1.9) 1.5 (1.3-1.8) 1.6 (1.3-1.9) NS 
  LDL mmol/L1 3.24±1.15 3.13±1.09 3.3±1.17 NS 
Insulin resistance     
  IR n(%) 147 (38.2) 25 (22.3) 122 (44.7) <0.001 
  DM n(%) 28 (7) 3 (2.5) 25 (8.9) 0.015 
  Glc mmol/L 4.9 (4.6-5.375) 4.8 (4.5-5.2) 5 (4.6-5.48) 0.009 
  Insulin pmol/L 60.05 (41.28-102.75) 
53.05 (34.18-
76.43) 
66.5 (43.78-118) 0.001 
  HOMA IR 1.96 (1.25- 3.35) 1.55 (1.01-2.42) 2.09 (1.33-3.72) 0.001 
  QUICKI 0.35 (0.32-0.37) 0.36 (0.33-0.38) 0.34 (0.31-0.37) 0.001 
Renal function     
  Full MDRD 82±21.24 88.56±18.76 79.13±21.63 <0.001 
Obesity     
  BMI 27.67±5.03 26.42±4.9 28.27±4.98 0.001 
  Results expressed as percentages, median (25-75th percentile values) or mean ± SD as appropriate 
NS: non significant, RA: Rheumatoid Arthritis, RF: Rheumatoid factor,  Anti-CCP: Anti-Cyclic Citrullinated Peptide,  CRP: 
C-Reactive Protein, ESR: Erythrocyte Sedimentation Rate, DAS: Disease Activity Score, HAQ: Health Assessment 
Questionnaire, EAD: Extra-Articular Disease, DMARDs: Disease Modifying Anti Rheumatic Drugs, MTX: Methotrexate, 
TNF: Tumor Necrosis Factor, CHOL: Cholesterol,  TG: Triglycerides,  HDL: High Density Lipoprotein, TC: Total 
Cholesterol,  LDL: Low Density Lipoprotein, IR: Insulin resistance, DM: Diabetes Mellitus, Glc: Glucose, HOMA 
IR:Homeostasis Model Assessment of IR, QUICKI: Quantitative Insulin sensitivity Check Index,  MDRD:  Modification of 
Diet in Renal Disease, BMI: Body Mass Index,  
 
1 patients not on statin (N=322, 80.5%) 
 
 
 
Table 2. Antihypertensive treatment in controlled and uncontrolled treated hypertensive rheumatoid arthritis patients
  Total (N=171) controlled  HTN 
(N=37)  
uncontrolled HTN 
(N=134) 
p value 
 
thiazide diuretic n(%) 78 (45.9) 19 (51.4) 59 (44.4) NS 
frusemide n(%) 16 (9.4) 2 (5.4) 14 (10.5) NS 
beta blocker HTN n(%) 47 (27.6) 10 (27) 37 (28.7) NS 
beta blocker sum n(%) 61 (35.9) 12 (32.4) 49 (36.8) NS 
ace inhibitors/ARBs n(%) 102 (60) 17 (45.9) 85 (63.9) 0.049 
dihydropyridine CCBs 41 (24.1) 6 (16.2) 35 (26.3) NS 
non dihydropyridine CCBs n(%) 6 (3.5) 0 (0) 6 (4.5) NS 
CCBs sum n(%) 46 (27.1) 6 (16.2) 40 (30.1) NS 
central blocker antihypertensives 
n(%) 
5 (2.9) 1 (2.7) 4 (3) NS 
a-adrenoreceptor blockers n(%) 9 (5.3) 2 (5.4) 7 (5.3) NS 
 
beta blockers HTN: beta blockers used for indication hypertension 
beta-blockers sum: used also for rate control, heart failure, angina, post myocardial infarction 
 
ARBs: Angiotensin Receptor Blockers, CCBs: Calcium Channel Blockers 
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Figure 1. Increased prevalence of uncontrolled hypertension in older Rheumatoid Arthritis 
(RA)  patients. 
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Figure 2. Increased prevalence of uncontrolled hypertension in Rheumatoid Arthritis (RA) 
patients with increased Body Mass Index (BMI) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key messages: 
• Hypertension is highly prevalent in RA patients 
• Hypertension is under-diagnosed mainly in young RA patients and 
under-treated mainly in the older patients with co morbid 
cardiovascular disease 
• Aggressive strategies for screening, treatment and monitoring of 
hypertension are required for the RA population 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
